EPR: 2022 biopharma trend predictions roundtable

Scroll Down

From supply challenges surrounding COVID-19 to regulatory changes and innovations, the year 2022 is set to be an interesting year for biopharma manufacturing companies around the world.

Here, Bill Vincent, Founder and Executive Chairman at Genezen provides his insights into the top biopharma trends we can expect to see in 2022. He also highlights the impact of regulatory changes on serum use for cell growth and the potential of stable producer cell lines throughout cell and gene therapy manufacturing.

Read the full article: Key challenges for biopharmaceutical manufacturing 2022

You may also be interested in...

Genezen delivers next phase of cGMP…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen, Monon Bioventures, and Purdue University…

Glioblastoma is one of the most aggressive types of cancer, affecting...

Read more

How can pseudotyping gammaretrovirus impact manufacturing?

Designing the plasmids that will be transfected into producer cells in...

Read more

ARM A-Cell: New guidance incorporates quality…

Lentiviruses are an essential tool for many cell and gene therapies...

Read more